Clinical Trial

A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess BMS-986500 as monotherapy in advanced solid tumors and as combination therapy in CDK4/6 inhibitor pre-treated advanced breast cancer.
Protocol Amendment History 15 amendments
This ClinicalTrials.gov record has been amended 15 times since 2025-05-21; most recent amendment 2026-07-09.
Status change: Not Yet Recruiting → Recruiting 2025-08-19
Trial Details
NCT Number NCT06997029
Lead Sponsor Bristol-Myers Squibb
Conditions Advanced Solid Tumor, Advanced Breast Cancer, Advanced Ovarian Cancer
Enrollment 234 participants
Start Date 2025-08-01
Primary Completion 2028-12-14 (estimated)
Study Completion 2028-12-14 (estimated)
Updated on ClinicalTrials.gov 2026-07-10